GZBL(SZ:002424) Cai Jing Wang·2026-02-02 08:11Core Viewpoint - ST Bailing (002424) expects a significant decline in net profit attributable to shareholders for the fiscal year 2025, projecting a loss between 60 million to 90 million yuan, representing a year-on-year decrease of 278.46% to 367.68% [1] Group 1: Financial Performance - The company anticipates a revenue decline of approximately 20% year-on-year for 2025 due to factors such as slowing product market demand, adjustments in medical insurance payment policies, and intensified market competition [1] - The increase in fixed asset scale has led to higher depreciation and amortization expenses, contributing to the overall rise in fixed costs and negatively impacting the net profit attributable to shareholders [1] Group 2: Strategic Response - Despite facing challenges from industry cyclical fluctuations, the company plans to continue pursuing its strategic development goals to adapt to the complex and changing environment of the pharmaceutical industry [1] - The company aims to expand market sales of its leading products and optimize its product structure to increase market share [1] - Continuous investment in research and development projects is planned to enrich the product pipeline and accelerate the market launch of new projects [1] - The company will enhance compliance management to effectively reduce various risks [1] Group 3: Management Confidence - The management team expresses confidence in the company's future operational development, committing to cost reduction and efficiency improvement initiatives to enhance operational quality and product competitiveness [2] - The focus will be on improving business performance and promoting sustainable development [2]